Rishika Sadam
Reuters -Denmark’s pharmaceutical company Novo Nordisk launched India’s blockbuster weight loss drug WEGOVY initially competing with the rival Eli Lilly in the public.
Nobo, who had previously planned for the release of drugs in 2026, is now starting to sell Wegovy in India, and in a few months, he probably said, “Perhaps in a few months,” and Reuters said about the anonymity because he has no authority to talk to the media.
“Nobo also evaluates the stock situation to deal with India’s demand. They want to avoid the lack of problems.”
The company’s acceleration plan follows the launch of ELI Lilly, an American rival for diabetes and obesity drugs in India last month.
Reuters reported that initially, Novo’s Indian team is promoting the world’s headquarters for the early launch of WEGOVY.
NOVO and LILLY have seen rapid increase in global demand for innovative weight loss drugs, and investors’ interest also has also improved pharmaceuticals into one of the most valuable companies in the world.
Competitive drugs belong to the treatment, known as GLP-1 receptor agent, which helps to control blood sugar and slow digestion, and it makes people feel richer for a long time.
Semaglutide, an active ingredient of NOVO’s Wegovy and Diabetes Medicine Ozempic, leaves a patent in India in 2026 and packs a way for general pharmaceutical producers to produce cheaper versions of drugs.
Local pharmaceuticals, such as Sun Pharma, Cipla and Reddy, are racing to build supplies based on the proportion of global market analysts.
Novo refused to mention it on Monday, but he said earlier that Wegovy was approved in India. At that time, the date of the release of India was not confirmed.
“NOVO also has a brand name Ozempic and Wegovy with better penetration in the market, and I think it will take advantage of this.”
Nevertheless, NOVO is a weekly march of LILLY and needs to provide drugs at a competitive price for injections.
(Treasure from Hyderabad’s Rishika Sadam and London’s Maggie Fick; Bill Berkrot)
